A large US health-record study published in BMJ Open found that newer GLP-1 receptor agonists, specifically semaglutide and tirzepatide, are associated with a lower risk of alcohol-related emergency department visits and hospitalizations among adults with alcohol use disorder who also have type 2 diabetes or obesity.
Alcohol use disorder (AUD) affects 10% of US adults, yet only 2% of adults with AUD receive medication-assisted treatment, according to data from BMJ Open. The economic burden of this crisis is immense, with an estimated cost exceeding $200 billion and more than 178,000 attributable deaths annually.
Reduced Hospitalization Risks for Semaglutide and Tirzepatide Users
Researchers utilized a target trial emulation framework to analyze de-identified Electronic Health Record (EHR) data from Truveta, a network representing more than 120 million patients across 30 US healthcare systems. The study tracked 40,703 adults diagnosed with AUD and either obesity or type 2 diabetes (T2D) who began treatment between January 1, 2018, and December 31, 2024.
The findings indicate that patients using newer GLP-1 receptor agonists experienced significantly fewer alcohol-related acute-care events compared to those on older or different medication classes.
The risk reduction was even more pronounced in patients treating obesity. According to News Medical, the hazard for alcohol-related hospitalizations was approximately 32% lower for those on newer GLP-1s compared to other anti-obesity medications (AOM), with 10.1% of the GLP-1 group recording such events versus 12.8% in the comparator group.
Patient Group
Comparator Drug
Risk Reduction (Hazard)
Type 2 Diabetes
Sulfonylureas
26% Lower
Type 2 Diabetes
Other ADM
22% Lower
Obesity
Other AOM
32% Lower
Notably, these benefits did not extend to older GLP-1 receptor agonists. The study found no significant difference in outcomes when newer agents were compared to their older counterparts.
Direct Impact on Alcohol Use Disorder Treatment
Beyond their use for metabolic health, the study evaluated the effect of GLP-1s when prescribed specifically as a treatment for AUD. In these scenarios, the medications were compared against standard AUD treatments such as naltrexone, disulfiram, and acamprosate.
Newer obesity drugs linked to fewer alcohol-related hospitalizations
The results for this specific application were stark. According to Nursing Times, patients with diabetes given a GLP-1 drug to treat their alcohol use disorder were 63% less likely to be admitted to the hospital for alcohol-related reasons than those receiving other treatments. For patients with obesity, that reduction in risk reached 65%.
“Initiation of newer GLP-1 receptor agonists among patients with alcohol-use disorder was associated with a lower observed risk of alcohol-related hospitalisation, with similar associations across populations with type 2 diabetes and obesity.”
Study authors, via Nursing Times
This suggests a potential mechanism involving the brain’s reward pathways. While these drugs are primarily known for reducing food noise and appetite by mimicking the glucagon-like peptide-1 hormone, they may similarly blunt the cravings associated with addictive substances, including nicotine and opioids.
Clinical Limitations and the Path to Randomized Trials
Despite the promising data, the researchers emphasize that these results are observational. Because the study relied on retrospective EHR data, there is a potential for residual confounding due to unmeasured lifestyle and socioeconomic factors.
Photo: Nursing Times
The current medical consensus remains cautious. While observational evidence suggests a link, BMJ Open notes that evidence from randomized clinical trials has been limited and mixed. For example, one randomized trial of semaglutide showed reductions in alcohol craving and drinks per drinking day, but failed to show a significant effect on the total number of drinking days or overall consumption.
“Further research, including randomised trials, is needed to evaluate the effectiveness of GLP-1 receptor agonists for alcohol use disoder.”
Photo: News Medical
Study authors, via Nursing Times
The divergence between these observational findings and randomized trial results likely stems from study design and population differences, such as whether the participants were actively seeking treatment. For now, the data suggests that while GLP-1s are powerful tools for metabolic health, their role in treating addiction is a promising hypothesis that requires rigorous clinical validation before becoming a standard of care.
The ability of tirzepatide to target both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) pathways may offer a different metabolic and neurological profile than semaglutide alone. If future trials confirm these findings, it could provide a critical alternative for adults with AUD who currently do not receive medication-assisted treatment due to the adherence and tolerability challenges of existing FDA-approved options.
